Board of directors

Magnus2

Magnus Persson

Chairman of the Board since 2016, born 1960. Member of the Remuneration Committee. Number of shares: 131 676

Magnus Persson is MD and associate professor in physiology at the Karolinska Institute in Stockholm. Persson has a large amount of experience in the fields of medicine, life sciences and biotech-financing. Persson has previously led development teams in clinical phase II and phase III programmes in the pharmaceutical industry and has founded and led private as well as public biotech and medtech companies, either as chairman or member of the board, in Europe and the USA. Persson has also been involved in multiple IPOs.

Persson is chairman of the board of Attgeno AB, Initiator Pharma AS, Eir Ventures Partners AB and associated companies, Addi Medical AB and Addi Optioner AB, and board member of Cerecor Inc.

Independent in relation to the Company and its management and the Company’s major shareholders.

Karin L

Karin Leandersson

Board member since 2016, born 1972. Member of the Audit Committee. Number of shares: 0

Karin Leandersson is a professor in tumour immunology at the medical faculty of Lund University. She has gained a wide range of cancer research experience in the fields of tumour immunology and tumour inflammation in solid tumours, mainly in breast cancer. Leandersson has also authored around 50 scientific publications in international journals.

Independent in relation to the Company and its management and the Company’s major shareholders.

Thoas F

Thoas Fioretos

Board member since 2010, born 1962. Member of the Audit Committee. Number of shares: 482 600

Thoas Fioretos is a professor and physician at the Department of Clinical Genetics at Lund University. The focus of his research is molecular and functional studies of genetic changes in leukaemia and how such changes can be used for diagnostic and therapeutic purposes. Fioretos has authored more than 120 scientific publications, and is one of the founders of Cantargia AB and bio-IT company Qlucore AB.

Fioretos is board member in Qlucore AB. Alternate board member in Neodos AB.

Independent in relation to the Company and its management and the Company’s major shareholders.

Patricia Delaite 600 13

Patricia Delaite

Board member since 2017, born 1963. Member of the Remuneration Committee. Number of shares: 0

Patricia Delaite is MD and MBA from University of Geneva and Lausanne. She is currently the Chief Medical Officer for Nouscom in Basel, and has had leading positions at AMAL Therapeutics, Incytes International Biosciences, ARIAD Pharmaceuticals, Novartis and Eli Lilly. Patricia has also 10 years previous experience in patient clinical management from the University hospital in Geneva.

Independent in relation to the Company and its management and the Company’s major shareholders.

Anders Martin Loef Red 05

Anders Martin-Löf

Board member since 2018, born 1971. Chairman of the Audit Committee. Number of shares: 24 000

Anders Martin-Löf has long experience as CFO for companies listed at the Stockholm stock exchange. He is CFO at Oncopeptides AB (publ) and was previously CFO at Wilson Therapeutics. Before that he has been CFO at RaySearch Laboratories and been responsible for investor relations and had different positions within business development at Swedish Orphan Biovitrum. He has a M.Sc. in Economics and Business from Stockholm University and a M.Sc. in Engineering Physics from the Royal Institute of Technology in Stockholm.

Independent in relation to the Company and its management and the Company’s major shareholders.

Flavia Borellini2

Flavia Borellini

Board member since 2020, born 1959. Number of shares: 0

Flavia Borellini holds a Ph.D. in Pharmaceutical Chemistry and Technology from the University of Modena, Italy.
She has broad experience in oncology and other therapeutic areas and has held senior positions with Astra Zeneca (Global Franchise Head, Hematology and Vice President, Global Product and Portfolio Strategy), Acerta Pharma (CEO), ONYX Pharmaceuticals (Vice President, Program Leadership), and Roche (Lifecycle Leader).
Dr. Borellini serves as a member of the board of directors of Kartos Therapeutics.

Independent in relation to the Company and its management and the Company’s major shareholders.

Magnus Nilsson Hemsida

Magnus Nilsson

Board member since 2021, born 1956. Number of shares: 0

Magnus Nilsson is founder, previously President and CEO, and since 2020 Senior Advisor at XVIVO Perfusion. He has also been President and CEO of Vitrolife and before that had various positions as Project Manager for drug development projects at Pharmacia & Upjohn, Pharmacia and Karo Bio. Magnus Nilsson is a Doctor of Medicine (Med Dr Sc) from Uppsala University and has published about twenty scientific articles.

Independent in relation to the Company and its management and the Company’s major shareholders.

Damian Hemsida

Damian Marron

Board member since 2021, born 1962. Number of shares: 0

Damian Marron has extensive experience as a board member and CEO in the life science industry, with a successful track record of leadership and value creation in public and private biotechnology companies. He has had positions as CEO and Executive vice president in several biotech companies. He is currently Chairman of the Board of Targovax ASA, Imophoron Ltd, CytoseeK Ltd and Board member of Bone Therapeutics and Resolys Bio and Head of Biopharma at Treehill Partners.
Marron holds a bachelor's degree in pharmacology from the University of Liverpool.
Independent in relation to the Company and its management and the Company’s major shareholders.